Turn Therapeutics Income Statement (2024-2026) | TTRX

Income Statement Sep2024 Dec2024 Mar2025 Sep2025 Dec2025 Mar2026
Shares Outstanding (Entity) (Quarter) 26.65M26.85M26.96M28.02M29.45M29.79M
Operating items
Research & Development (Quarter) 0.15M0.01M0.01M0.16M0.06M0.11M
Wages, Salaries and Other (Quarter) 0.07M0.30M
Selling, General & Administrative (Quarter) 0.52M0.32M0.38M1.75M2.16M1.14M
Restructuring Costs (Quarter) 0.11M0.29M
Other Operating Expenses (Quarter) -0.11M-0.03M-0.29M
Operating Expenses (Quarter) 0.67M0.33M0.38M1.91M2.19M1.25M
Operating Income (Quarter) -0.67M-0.33M-0.38M-1.91M-2.19M-1.25M
EBIT (Quarter) -0.67M-0.33M-0.38M-1.91M-2.19M-1.25M
Non-operating items
Interest & Investment Income (Quarter) 0.01M0.01M0.01M0.01M0.01M0.05M
Other Non Operating Income (Quarter) 0.05M0.00M0.12M0.01M
Non Operating Income (Quarter) 0.01M0.01M0.06M0.01M2.47M0.28M
Net income details
EBT (Quarter) -1.03M-0.47M-0.57M-7.58M-2.93M-3.15M
Profit After Tax (Quarter) -0.67M-0.32M-0.33M-1.90M-1.24M-0.97M
Income from Continuing Operations (Quarter) -1.03M-0.47M-0.57M-7.58M-2.93M-3.15M
Consolidated Net Income (Quarter) -1.03M-0.47M-0.57M-7.58M-2.93M-3.15M
Income towards Parent Company (Quarter) -1.03M-0.47M-0.57M-7.58M-2.93M-3.15M
Net Income towards Common Stockholders (Quarter) -1.03M-0.47M-0.57M-7.58M-2.93M-3.15M
Additional items
EPS (Basic) (Quarter) -0.04-0.02-0.02-0.27-0.11-0.11
EPS (Diluted) (Quarter) -0.04-0.02-0.02-0.27-0.11-0.11
Shares Outstanding (Quarter) 26.65M26.64M26.96M27.98M27.72M29.48M
Shares Outstanding (Diluted) (Quarter) 26.65M26.64M26.96M27.98M27.72M29.48M
EBITDA (Quarter) -0.67M-0.33M-0.38M-1.91M-2.19M-1.25M
Interest Expenses (Quarter) 0.36M0.15M0.19M5.67M0.75M1.95M